TNF and infection: The incidence of serious adverse events such as infections was significantly higher in the group treated with the anti-TNF-α agent compared to placebo (34% versus 9%, p = 0.04) as well as the 6-month mortality rate (58% versus 23%, respectively, p = 0.017) [120].